Literature DB >> 8729948

A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study.

S Baruchel1, M Bernstein, V M Whitehead, S Devine, B Bell, R Dubowy, H Grier, C Kretschmar, A M Langevin, T Vietti.   

Abstract

Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M2 daily for five days. Six patients including three patients with brain tumor had stable disease.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8729948     DOI： 10.1007/BF00873802

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  16 in total

1.  Objective antitumor activity of acivicin in patients with recurrent CNS malignancies: a Southwest Oncology Group trial.

Authors:  S A Taylor; J Crowley; T W Pollock; H J Eyre; C Jaeckle; H E Hynes; R L Stephens
Journal:  J Clin Oncol       Date:  1991-08       Impact factor: 44.544

2.  Action and sequence dependent interaction of acivicin and 6-thioguanine in human derived malignant T-ALL and CALLA+ cell lines.

Authors:  R C Trueworthy; R A DeAbreu; L H Lambooy; J P Bökkerink; E H Stet
Journal:  Adv Exp Med Biol       Date:  1991       Impact factor: 2.622

3.  The inhibition of gamma-glutamyl transpeptidase and glutathione metabolism of isolated rat kidney cells by L-(alpha S, 5S)-alpha-amino-3-chloro-4, 5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501).

Authors:  D J Reed; W W Ellis; R A Meck
Journal:  Biochem Biophys Res Commun       Date:  1980-06-30       Impact factor: 3.575

4.  Glutathione and glutathione conjugate efflux from cultured liver cells.

Authors:  M J Meredith
Journal:  Cell Biol Toxicol       Date:  1991-01       Impact factor: 6.691

5.  Phase II trial of acivicin in advanced metastatic breast cancer.

Authors:  G Fleishman; H Y Yap; W K Murphy; G Bodey
Journal:  Cancer Treat Rep       Date:  1983-09

6.  Phase I study of acivicin and cisplatin in non-small-cell lung cancer. A National Cancer Institute of Canada study.

Authors:  J A Maroun; D J Stewart; S Verma; W K Evans; E Eisenhauer
Journal:  Am J Clin Oncol       Date:  1990-10       Impact factor: 2.339

7.  Pharmacokinetic and biochemical studies on acivicin in phase I clinical trials.

Authors:  J P McGovren; E A Pratt; R J Belt; S A Taylor; R S Benjamin; B Ardalan; T Ohnuma
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

8.  Influence of glutamine on the growth of human glioma and medulloblastoma in culture.

Authors:  G Dranoff; G B Elion; H S Friedman; G L Campbell; D D Bigner
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

9.  Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion.

Authors:  R H Earhart; J M Koeller; T E Davis; E C Borden; J P McGovren; H L Davis; D C Tormey
Journal:  Cancer Treat Rep       Date:  1983 Jul-Aug

10.  Phase I and pharmacological study of acivicin by 24-hour continuous infusion.

Authors:  G R Weiss; J P McGovren; D Schade; D W Kufe
Journal:  Cancer Res       Date:  1982-09       Impact factor: 12.701
View more
  2 in total

1.  Establishing a Preclinical Multidisciplinary Board for Brain Tumors.

Authors:  Birgit V Nimmervoll; Nidal Boulos; Brandon Bianski; Jason Dapper; Michael DeCuypere; Anang Shelat; Sabrina Terranova; Hope E Terhune; Amar Gajjar; Yogesh T Patel; Burgess B Freeman; Arzu Onar-Thomas; Clinton F Stewart; Martine F Roussel; R Kipling Guy; Thomas E Merchant; Christopher Calabrese; Karen D Wright; Richard J Gilbertson
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

2.  Role of hydroquinone-thiol conjugates in benzene-mediated toxicity.

Authors:  Serrine S Lau; Christopher L Kuhlman; Shawn B Bratton; Terrence J Monks
Journal:  Chem Biol Interact       Date:  2009-12-23       Impact factor: 5.192
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.